Alexia Filipputti, PharmD, is responsible for managing and licensing technologies arising from the department of pathology at both Mass General Hospital and Brigham and Women’s Hospital. Prior to joining Mass General Brigham Innovation, she worked for Business France, as part of their North America health care team, where she supported innovative French Healthtech and Life Sci companies, finding strategic partnerships with key stakeholders in the US. She also served as a mergers and acquisitions analyst for Urgo and Bpifrance Financement.
Alexia earned her PharmD from University of Strasbourg, a Masters in Immunology and Immunopathology from University Pierre and Marie Curie, and an advanced Masters in strategy and management of international business from ESSEC Business School.